Arvind Arora

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan et al. · The Lancet Oncology · 2021 · 711 citations · Full text

The Attractive Female Body Weight and Female Body Dissatisfaction in 26 Countries Across 10 World Regions: Results of the International Body Project I

Viren Swami, David A. Frederick, Toivo Aavik et al. · Personality and Social Psychology Bulletin · 2010 · 699 citations

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan et al. · Journal of Clinical Oncology · 2019 · 226 citations

Cancer Management, Prognosis, Pathology +17

Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT–YB1–MDR1 Signaling Pathway

Dongliang Mo, Hongbo Fang, Kaifeng Niu et al. · Cancer Research · 2016 · 101 citations · Full text

Untangling the ATR‐CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer

Tarek M.A. Abdel-Fatah, Fiona K. Middleton, Arvind Arora et al. · Molecular Oncology · 2014 · 84 citations · Full text